Rafael Amado has sold stock and made no open-market buys since Oct 2020

Rafael G. Amado, M.D. (referred to as Amado Rafael in some contexts) is President and Head of Global R&D at Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative biopharmaceutical company focused on oncology, autoimmune disorders, infectious diseases, and neuroscience.( He assumed the role of Head of Global Oncology R&D in December 2022 and expanded to oversee all Global R&D following Harald Reinhart's retirement in June 2024.( As a key executive reporting to CEO Dr. Samantha Du, Dr. Amado leads global research, development, and pipeline advancement across therapy areas.(

Dr. Amado brings extensive expertise in oncology drug development, previously serving as Executive Vice President, Head of R&D and Chief Medical Officer at Allogene Therapeutics (2019–2022), President of R&D and CMO at Adaptimmune (2018–2019), and Senior Vice President and Global Head of Oncology R&D at GlaxoSmithKline (2008–2015), among other roles at Amgen and academic positions at UCLA.( He earned his M.D. from the University of Seville School of Medicine, completed residency in Internal Medicine, and fellowship in Hematology/Oncology at UCLA.( Recently, as a corporate insider, he sold 10,787 ADS for $188,033.59 on December 31, 2025.(

Written by Perplexity from public sources.